Anke Hemmerling, MD, PhD, MPH

Associate Adjunct Professor
Campuswide Accounting
+1 510 664-9881

Anke Hemmerling, MD PhD MPH, is an Associate Adjunct Professor in the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences, and the Director of the Interdisciplinary MPH Program in the UC Berkeley School of Public Health.

She received her medical and public health training at the Humboldt University in Berlin (Germany) and at the University of California, Berkeley (UCB). During her clinical training, she repeatedly worked in health projects and hospitals in Latin America.

Always with a focus on global women’s health, her early career research covered medication abortion, infertility and fertility choices, and safe motherhood.
Her current clinical research is focusing on the prevention of HIV and other genital infections such as bacterial vaginosis in women, conducting a number of clinical trials in the US and South Africa. She served as the protocol co-Chair of the NIH-sponsored multi-site phase 2B study for the prevention of bacterial vaginosis using the live biotherapeutic product LACTIN-V.

At UC San Francisco and UC Berkeley, she is mentoring and teaching several courses for medical students, undergraduate and graduate students, as well as post-doctoral students in several educational programs.

Dr. Hemmerling serves as a senior technical adviser for the Initiative for Multipurpose Prevention Technologies for Reproductive Health (IMPT) and on several data safety monitoring boards for federally funded clinical studies. In addition, she is a member of the Education Committee at the UCGHI Center of Expertise in Women’s Health, Gender and Empowerment.

Areas of Interest:
• Prevention of sexually transmitted infections (STI)
• Drug development: Microbicides and live biotherapeutic products to prevent HIV/STI
• Fertility Choices
• Safe Motherhood

Publications: 

Treatment Success Following Standard Antibiotic Treatment for Bacterial Vaginosis Is Not Associated With Pretreatment Genital Immune or Microbial Parameters.

Open forum infectious diseases

Armstrong E, Hemmerling A, Joag V, Huibner S, Kulikova M, Crawford E, Castañeda GR, Anzala O, Obila O, Shahabi K, Ravel J, Coburn B, Cohen CR, Kaul R

Recovery and Resilience in the Canal Community: Economic Impacts and Solutions During the COVID-19 Pandemic.

Journal of racial and ethnic health disparities

Bichkoff H, Huerta Niño R, Hemmerling A, Ho K, Huancas CG, Burke A, Guzman V, Allen R, Coe L, Salazar E, Wong M

Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.

The Lancet. Microbe

Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Nagelkerke N, Coburn B, Cohen CR, Kaul R

Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli.

The Journal of clinical investigation

Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Liu R, Crawford ED, Castañeda GR, Nagelkerke N, Coburn B, Cohen CR, Kaul R

Connecting the Dots: Translating the Vaginal Microbiome Into a Drug.

The Journal of infectious diseases

Lagenaur LA, Hemmerling A, Chiu C, Miller S, Lee PP, Cohen CR, Parks TP

Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. Reply.

The New England journal of medicine

Cohen CR, Parks T, Hemmerling A

Bridging the gap: advancing multipurpose prevention technologies from the lab into the hands of women†.

Biology of reproduction

Young Holt B, Kiarie J, Kopf GS, Nanda K, Hemmerling A, Achilles SL

Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.

The New England journal of medicine

Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, Hemmerling A

Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus.

The Journal of rheumatology

Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ

A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A

Nutrition Education in Internal Medicine Residency Programs and Predictors of Residents' Dietary Counseling Practices.

Journal of medical education and curricular development

Khandelwal S, Zemore SE, Hemmerling A

Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women.

Seminars in reproductive medicine

Seidman D, Hemmerling A, Smith-McCune K

Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach.

BJOG : an international journal of obstetrics and gynaecology

Young Holt B, Romano J, Manning J, Hemmerling A, Shields W, Vyda L, Lusti-Narasimhan M

Prioritizing multipurpose prevention technology development and investments using a target product profile.

Antiviral research

Romano J, Manning J, Hemmerling A, McGrory E, Holt BY

Developing multipurpose reproductive health technologies: an integrated strategy.

AIDS research and treatment

Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B

Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations.

Sexually transmitted diseases

Hemmerling A, Harrison WG, Brown JM, Moscicki B, Oziemkowska M, Bukusi EA, Cohen CR

Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05.

Sexually transmitted diseases

Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, Fredricks DN, Cohen CR

Probiotics: the potential for a live microbicide to prevent HIV.

Journal of acquired immune deficiency syndromes (1999)

Hemmerling A, Cohen CR

Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis.

Sexually transmitted diseases

Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Foster-Rosales A, Cohen CR

Women front and center: the opportunities of involving women in participatory health research worldwide.

Journal of women's health (2002)

Decker M, Hemmerling A, Lankoande F

Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.

Sexually transmitted diseases

Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR

Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally.

Journal of women's health (2002)

Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA

The safety of misoprostol.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Hemmerling A

The worldwide burden of postpartum haemorrhage: Policy development where inaction is lethal.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Potts M, Hemmerling A

Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association.

BJOG : an international journal of obstetrics and gynaecology

Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H, Gonzalez WV, Cordero M, Calderon V

Emotional impact and acceptability of medical abortion with mifepristone: a German experience.

Journal of psychosomatic obstetrics and gynaecology

Hemmerling A, Siedentopf F, Kentenich H

Couples becoming parents: something special after IVF?

Journal of psychosomatic obstetrics and gynaecology

Ulrich D, Gagel DE, Hemmerling A, Pastor VS, Kentenich H

Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency.

Clinical nephrology

Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products.

The Clinical investigator

Wagner D, Wagenbreth I, Stachan-Kunstyr R, Thoma HA, Hemmerling AE, Flik J